Notícias

Apple's Latest Acquisition Signals a Bigger Push Into AI and Advanced Chips

The UK drugmaker is reportedly talking to Bristol Myers Squibb about a nearly $400 billion tie-up, but investors are struggling to diagnose the logic.

The fund holds 80 private companies and focuses on Y Combinator startups, with shares expected to list on the NYSE on August 13

Rocket Lab is rapidly transforming from a launch company into a diversified space business, positioning it for profits and strong free cash flow as early as next year.

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.

One of the largest global pharma companies would be created if a deal were to materialise.

BMY surged roughly 6% in premarket trading on the news before fading; the stock is now trading near flat. The asymmetric price reaction captures the market's immediate verdict: AZN shareholders see a value-destructive deal, while BMY holders see a potential premium exit.

Space Exploration Technologies or SpaceX's (SPCX) current valuation appears attractive after shares

European stock markets closed mostly higher in Monday trading as the Stoxx Europe gained 0.4%, Germa

Also, the e-bike startup spun off from Rivian Automotive Inc., will reportedly begin delivering its first e-bikes next week, ending months of delays that pushed back its original spring launch. The Launch Edition of its $4,500 TM-B e-bike has started...

The company's stock took quite a body blow after it reported first-quarter earnings.

The firm uses AI and machine-learning models to detect signs of coercion or manipulation in digital transactions, helping banks distinguish criminal activity from legitimate ones in real time.

Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.

AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb.

A combination of the two pharmaceutical companies could create an entity valued at nearly $400 billion, according to the Financial Times

Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets in recent weeks, while technology stocks attempted to extend their recovery following July’s sharp pullback.

SoundHound AI has built something rare in the voice-AI space: a platform that major automakers, restaurant chains, banks, and smart TV brands all depend on. Now, with shares down sharply and a transformative merger pending, several trillion-dollar companies have real reasons to consider writing a check.

SpaceX began trading on June 12, 2026, with an IPO price of $135 per share, giving retail investors an opportunity to buy into one of the world’s most closely watched aerospace companies. A $5,000 investment at the IPO price would have purchased about 37.04 shares. By June 16, those shares had climbed to $225.64, increasing […] The post If You Invested $5K in the SpaceX IPO, How Much Do You Have Now? appeared first on SmartReads by SmartAsset.

The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion.

SkyWater will continue serving aerospace, defence, and commercial markets while adding IonQ’s quantum technologies.

If maintained until close, the decline would be the stock’s biggest one-day percentage fall since the day of the 2024 U.S. presidential election.

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

United Airlines' failed approaches to Delta and American appear to make little sense. Investors should trust the CEO anyway.

Axon Enterprise has posted consecutive quarter-over-quarter revenue gains, while Chipotle's growth has proven more uneven — a divergence that could reshape investor expectations.

Tesla Inc. CEO Elon Musk has dismissed reports of the EV giant mulling the sale of its Chinese arm that could have reportedly paved the way for a potential merger with Space Exploration Technologies Corp.. Elon Musk Says Sale Has...

Investing.com -- AstraZeneca PLC (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) have held talks in recent months about a deal that would combine the companies into one, according to a Financial Times report.

AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb in a deal likely to raise fresh questions over the company’s ties to the UK.

Wall Street finally got a taste of Blackstone-backed Jersey Mike’s, yet the first bite looked hesitant. What’s next for JMKE?

Which of these three high-tech market newcomers is the best?